Expertise without borders.
Across all therapeutic areas, technologies, routes of administration, dosage forms and company types.
Regulatory cues cross borders.
Stakeholders influence approvals, while pre- and post-market adverse events directly affect the availability of new medical products. These safety indicators act as regulatory cues for product development and can predict regulatory conservatism.
We create pathways where no precedent or guidance exists. Because no two products or programs are alike, we distill each scientific and clinical program to the benefit-risk essence a regulator needs to understand.
Expertise without borders.
Seven offices, four continents and regulatory experience extending across more than 100 markets.
Active network
Boston HQ → Boston
Regulatory network / live routing
01
Global office
01 / 07
Select an office below
One team across every border.
Share the regulatory decision, development challenge or pathway that needs experienced judgment.
Schedule a consultation